Back to top

The Zacks Analyst Blog Highlights: Alphabet, Walgreens Boots, Johnson & Johnson and Amazon

Read MoreHide Full Article

For Immediate Release

Chicago, IL –December 24, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Alphabet (GOOGL - Free Report) , Walgreens Boots Alliance (WBA - Free Report) , Johnson & Johnson (JNJ - Free Report) and Amazon (AMZN - Free Report) .

Here are highlights from Friday’s Analyst Blog:

Alphabet Ties Up with Walgreens, Boosts Healthcare Presence

Alphabet’s healthcare division Verily has teamed up with Walgreens Boots Alliance in a bid to strengthen presence in the sector. This partnership is the first of its kind in the pharmacy space.

Both the companies have agreed to work on several healthcare projects together with an aim to make healthcare services affordable for the mass.

The companies are focused on the healthcare management for the people living with chronic diseases by reducing the cost structure for them.

The latest deal seems to be a win-win situation for both the companies. Walgreens will now be able to leverage Verily’s robust technologies to develop better healthcare solutions.

Further, the deployment of Verily’s technology at Walgreens pharmacies will boost the adoption rate of its technology.

Improving Healthcare Initiatives

The latest partnership provides is a testament to Alphabet’s rising healthcare initiatives. Moreover, growing strategic partnerships in healthcare sector will aid the company in rapidly penetrating this multi-trillion market.

To begin with the multiple healthcare projects with Walgreens, Verily is working on a medication adherence pilot project which involves deployment of technically advanced devices to ensure the reach of proper medication to patients.

Further, Onduo, a joint venture (JV) between Verily and Sanofi will collaborate with Walgreens to develop a virtual solution for Type 2 diabetes. Notably, this will be developed via Walgreens employee health plan for the company’s employees.

Apart from the recent partnership, Verily has collaborated with Johnson & Johnson to work on a startup named Verge Surgical in order to develop a surgical robot.

Further, Verily is set to form a JV with ResMed with an aim to help people with undiagnosed and untreated sleep apnea by developing a technology which will aid in the diagnosis of this disease.

Additionally, the company is currently working with Dexcom on the creation of a miniaturized glucose monitor, in turn bolstering efforts toward developing non-intrusive glucose-measuring devices.

Intensifying Battle

The heavy dependence of healthcare sector on technology is creating big opportunities for tech companies to foray into this particular space with their robust skills and techniques.

Apart from Alphabet, the healthcare sector has been able to attract many tech companies like Amazon, Apple and Fitbit, to name a few.

Amazon’s aggressive strategies pose major challenges to Alphabet’s growing initiatives in the sector. Amazon’s announcement of PillPack acquisition remains its biggest step in the sector.

However, Alphabet, by partnering with Walgreens is taking the game to Amazon. Moreover, strong advances that are being made by Verily remain tailwinds for the company.

Currently, Alphabet carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.

Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.

See the pot trades we're targeting>>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com                                      

http://www.zacks.com                                                   

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.



More from Zacks Press Releases

You May Like